All In Biotech

Drug Trial Radar · NCT03137381

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

149

Actual

Start

Aug 9, 2017

Primary completion

Jul 8, 2019

Study completion Jul 8, 2019

Sponsor

Lead sponsor
Concert PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.

Conditions

  • Alopecia Areata

Interventions

  • CTP-543Drug

    Administered as tablets.

  • CTP-543 matching placeboDrug

    Administered as tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving at Least a 50% Relative Reduction in Severity of Alopecia Tool (SALT) Score From Baseline at Week 24Time frame: Week 24
  2. Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: From first dose of study drug up to safety follow up at Week 28

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California

  • Contour Dermatology & Cosmetic Surgery Center

    Rancho Mirage, California

  • Stanford University School of Medicine

    Redwood City, California

  • Kaiser Permanente Northern California

    San Francisco, California

  • Yale School of Medicine

    New Haven, Connecticut

  • Siperstein Dermatology Group

    Boynton Beach, Florida

  • Northwestern University

    Chicago, Illinois

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • Icahn School of Medicine at Mt. Sinai

    New York, New York

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Northwest Dermatology

    Portland, Oregon

  • Suzanne Bruce & Associates, PA

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.